Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

sALT629

Name: sALT629
Brand: TargetMol
SKU: T214188
Rating: 4.5 (1 reviews)

Catalog No. T214188 Copy Product Info

🥰Excellent

sALT629 is an orally active antituberculosis agent with potent intracellular activity in macrophages (EC50 value of 1.5 μM). It exhibits broad-spectrum activity against Mycobacterium tuberculosis (Mtb) across four different carbon sources, maintaining efficacy against drug-resistant strains and active against both slow-replicating and non-replicating Mtb. When combined with oxazolidinone drugs like Linezolid and Sutezolid, sALT629 shows synergistic activity. This compound is suitable for tuberculosis research.

sALT629

Copy Product Info

🥰Excellent

Catalog No. T214188

sALT629

Cas No. 484026-63-3

Pack Size	Price	USA Stock	Global Stock	Quantity
10 mg	Inquiry	10-14 weeks	10-14 weeks
50 mg	Inquiry	10-14 weeks	10-14 weeks

For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)

Add to Quotation

For research use only—not for human use. No sales to individuals. Use as intended only.

Questions

Resource Download

Product Introduction

Bioactivity

Description	sALT629 is an orally active antituberculosis agent with potent intracellular activity in macrophages (EC50 value of 1.5 μM). It exhibits broad-spectrum activity against Mycobacterium tuberculosis (Mtb) across four different carbon sources, maintaining efficacy against drug-resistant strains and active against both slow-replicating and non-replicating Mtb. When combined with oxazolidinone drugs like Linezolid and Sutezolid, sALT629 shows synergistic activity. This compound is suitable for tuberculosis research.
In vitro	sALT629 exhibits inhibitory activity against Mtb cultured with four different carbon sources (acetate, butyrate, cholesterol, and glucose), with an EC50 of 1.5 μM within macrophages. It demonstrates a MIC of 0.8-1.7 μM against multidrug-resistant (MDR), extensively drug-resistant (XDR), and mono-drug-resistant Mtb strains, and remains active against both slow-replicating and non-replicating Mtb. In 7H12 cholesterol media, sALT629 (1.7-13.6 μM; 7 days) shows dose-dependent bactericidal activity. In the Hu-Coates 100-day dormancy model, sALT629 (20 μM; 7 days) reduces CFU by about 1.5 log units, and in the Loebel nutrient deprivation model, it reduces CFU by approximately 0.5 log units. With concentrations greater than 40 μM, sALT629 does not exhibit significant cytotoxicity towards HEK293T and HepG2 cells, maintaining a selectivity index (SI) greater than 23. The compound shows synergistic effects with oxazolidinone drugs (Linezolid, Sutezolid) having a FIC of 0.5, additive effects with drugs like TBD11, TBA-7371, and Q203 (FIC=0.63-1.0), and no significant interaction with drugs such as Isoniazid (FIC>1.0).
In vivo	sALT629 (administered at 30-100 mg/kg twice daily or 200 mg/kg once daily, orally, for four consecutive days) exhibits no significant toxicity in CD-1 mice, with no observed weight loss or abnormalities in clinical biochemistry and hematology parameters. Administering sALT629 at 100 mg/kg twice daily or 200 mg/kg once daily maintains plasma concentrations above EC50 for over 24 hours, with lung tissue exposure exceeding EC50.

Chemical Properties

Molecular Weight	275.31
Formula	C₁₃H₁₇N₅O₂
Cas No.	484026-63-3
Smiles	O=C(N)CN1N=NC(=N1)C2=CC=C(OCC(C)C)C=C2

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature.

Citations

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc